High Dose Busulphan/Cyclophosphamide for Autologous Bone Marrow Transplantation is Associated with Minimal Non-Hemopoietic Toxicity

References

• De Vita V. T., Hellman S., Rosenberg S. A. Principles and Practice of Oncology, 3rd edn. Lippincott, Philadelphia 1989; 276–296
   Google Scholar
• Cheson Lacerna B. D.L., Leyland-Jones B., Sarosy G., Wittes R. E. Autologous bone marrow transplantation. Current status and future directions. Ann. Intern. Med. 1989; 110: 51–65
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Boyd A. W., Green M. D., et al. High-dose chemotherapy with busulphan and cyclophosphamide and bone marrow transplantation for drug-sensitive malignancies in adults: A preliminary report. Med. J. Austr. 1989; 151: 379–386
   PubMed Web of Science ®Google Scholar
• Santos G. W., Tutschka P. J., Brookmeyer R., et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 1983; 309: 1347–1353
   PubMed Web of Science ®Google Scholar
• Tutschka P. J., Copelan E. A., Klein J. P. Bone marrow transplantation for leukaemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 5: 1382–1388
   Google Scholar
• Nemunaitis J., Rabinowe S. N., Singer J. W., et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N. Engl. J. Med. 1991; 324: 1773–1778
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Wolf M., Lusk J., et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; Oct. 14: 891–895
   Google Scholar
• Sheridan W. P., Begley C. G., Juttner C. A., et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; Mar. 15: 640–644
   Web of Science ®Google Scholar
• Bearman S. I., Applebaum F. R., Buckner C. D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol. 1988; 6: 1562–1568
   PubMed Web of Science ®Google Scholar
• Jones R. J., Lee K. S. K., Beschorner W. E., et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–783
   PubMed Web of Science ®Google Scholar
• Oken M. M., Creech R. H., Tormey D. C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. (CTT) 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Brodsky R., Topolsky D., Crilley P., Bulova S., Brodsky I. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am. J. Clin. Oncol. 1990; 13: 221–225
   PubMed Web of Science ®Google Scholar
• Chopra R., Goldstone A. H., McMillan A. K., et al. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: The British Autograft Group. J. Clin. Oncol. 1990; 10: 1840–1847
   Google Scholar
• Meloni G., Porcellini A., Carotenuto M., et al. Busulfan and cyclophosphamide (bu-cy) as conditioning regimen for autologous BMT in acute lymphoblastic leukemia (ALL). Blood 1990; 76: 553a, abstract
   Google Scholar
• Stiff P., McKenzie R., Sosman J., Koch D., Fisher R. High dose busulfan and cyclophosphamide with bone marrow rescue for refractory Hodgkin's disease: A tolerable and effective regimen in patients without prior nitrosourea exposure. Blood 1990; 76: 567, abstract
   Google Scholar
• Essell J. H., Thompson J. M., Harman G. S., et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 76: 2784–2788
   Google Scholar
• Morgan M., Dodds A., Atkinson K., Szer J., Downs K., Briggs J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br. J. Haematol. 1991; 77: 529–534
   PubMed Web of Science ®Google Scholar
• Neville T. J., Barnett M. J., Klingemann H. G., Reece D. E., Shepherd J. D., Phillips G. L. Regimen related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J. Clin. Oncol. 1990; 7: 1224–1232
   Google Scholar
• Grigg A. P., Shepherd J. D., Philips G. L. Busulphan and phenytoin. Ann. Intern. Med. 1989; 111: 1049–1050
   PubMed Web of Science ®Google Scholar
• Vellek M., Brown R. Evaluation of Ondansetron in preparative regimens for bone marrow transplantation: A pilot study. Blood 1991; 78: 508a, abstract
   Google Scholar
• Attal M., Huguet F., Rubie H., et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992; 79: 2834–2840
   PubMed Web of Science ®Google Scholar
• Gluckman E., Jolivet I., Scobohaci M. L., et al. Use of prostaglandin El for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br. J. Haematol. 1990; 74: 277–281
   PubMed Web of Science ®Google Scholar
• Lieschke G. J., Ranmenghi U., O'Connor M. P., et al. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br. J. Haematol. 1992; 82: 589–595
   PubMed Web of Science ®Google Scholar